Detailed in vitro analyses of the impact of multimodal cancer therapy with hyperthermia and radiotherapy on the immune phenotype of human glioblastoma cells. (31st December 2022)

• Record Type: Journal Article
• Authors: Stoll, Eileen; Hader, Michael; Rückert, Michael; Weissmann, Thomas; Lettmaier, Sebastian; Putz, Florian; Hecht, Markus; Fietkau, Rainer; Rosin, Andreas; Frey, Benjamin; Gaipl, Udo S.
• Is Part Of: International journal of hyperthermia. Volume 39:Number 1(2022)
• Page Start: 796
• Page End: 805
• Publication Date: 2022-12-31
• Subjects: Hyperthermia -- radiotherapy -- immune checkpoint molecules -- danger signals -- glioblastoma -- multimodal cancer therapy; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2022.2080873
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Purpose: Improvements of heat-delivery systems have led to hyperthermia (HT) being increasingly recognized as an adjunct treatment modality also for brain tumors. But how HT affects the immune phenotype of glioblastoma cells is only scarcely known. Materials and Methods: We therefore investigated the effect of in vitro HT, radiotherapy (RT), and the combination of both (RHT) on cell death modalities, immune checkpoint molecule (ICM) expression and release of the danger signal HSP70 of two human glioblastoma cell lines (U87 and U251) by using multicolor flow cytometry and ELISA. Hyperthermia was performed once or twice for 60-minute sessions reaching temperatures of 39 °C, 41 °C, and 44 °C, respectively. RT was administered with 5 x 2 Gy. Results: A hyperthermia chamber for cell culture t-flasks regulating the temperature via a contact sensor was developed. While the glioblastoma cells were rather radioresistant, particularly in U251 cells, the combination of RT with HT significantly increased the percentage of apoptotic and necrotic cells for all temperatures examined and for both, single and double HT application. In line with that, an increased release of HSP 70 was seen only in U251 cells, mainly following treatment with HT at temperatures of 44 °C alone or in combination with RT. In contrast, immune suppressive (PD-L1, PD-L2, HVEM) and immune stimulatory (ICOS-L, CD137-L and Ox40-L) ICMs were significantly increased mostly on U87 cells, and particularly after RHT with 41 °C. Conclusions: Individual assessment of the glioblastoma immune cell phenotype with regard to the planned treatment is mandatory to optimize multimodal radio-immunotherapy protocols including HT.